

Special Issue

Therapy in Neuro-Oncology

Message from the Guest Editor

The therapeutic landscape of neuro-oncology continues to evolve rapidly despite profound therapeutic challenges. Advances in cancer neuroscience, increasingly refined molecular classification of primary central nervous system tumors, and the development of novel therapies are reshaping patient care. This Special Issue highlights these developments across both adult and pediatric populations. Topics include updates on important areas such as IDH inhibitor therapy and therapeutic strategies in cancer neuroscience, as well as emerging data on immunotherapies such as CAR-T and cancer vaccines. There are also contributions on molecular diagnosis and management of meningiomas, along with evolving diagnostic and management strategies for metastatic disease, including brain metastases and leptomeningeal disease. Finally, advances in modern technology and supportive care highlight a growing emphasis on precision medicine, multidisciplinary care, and patient-centered outcomes in neuro-oncology.

Guest Editor

Dr. Herbert B. Newton

1. Neuro-Oncology Center and Brain Tumor Institute, Seidman Cancer Center, University Hospitals of Cleveland Medical Center, Cleveland, OH, USA
2. Molecular Oncology Program, Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve University, Cleveland, OH, USA

Deadline for manuscript submissions

30 September 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/270699

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)